Metabolism open最新文献_第8页

Component-based approach of enhanced recovery after surgery protocols in bariatric surgery: A systematic review and meta-analysis of randomized controlled trials 在减肥手术中增强术后恢复的基于组件的方法：随机对照试验的系统回顾和荟萃分析

Metabolism open

Pub Date : 2025-06-14 DOI: 10.1016/j.metop.2025.100376

Ibrahim Ezuddin M. Almaski , Yazan Jumah Alalwani , Reem Salem Alshammari , Rayyan Mohammed A. Alassiri , Salman Ahmed S. Jathmi , Aishah Mohammed Alhadi , Amal Saleh Alzahrani , Mohammed Abdulwahed Alzahrani , Ahmed Y. Azzam , Tareq A. Maani

Introduction

Enhanced recovery after surgery (ERAS) protocols are evidence-based care improvement processes designed to minimize and reduce the negative physiological consequences of surgery. While previous studies have investigated ERAS in bariatric surgery, none have evaluated which specific components contribute most significantly to improved outcomes.

Methods

We performed a systematic review and meta-analysis following PRISMA 2020 guidelines. Six randomized controlled trials (RCTs) with total of 740 patients comparing ERAS protocols to standard care in bariatric surgery were included. We conducted component-specific meta-regression analysis of 14 individual ERAS elements, dose-response analysis across three implementation levels (low: ≤4 components, medium: 5–8 components, high: ≥9 components), and component clustering to identify synergistic combinations. Meta-regression was used to determine the relative impact of individual components on recovery and safety outcomes.

Results

Six RCTs including a total of 740 patients were included. Patients randomized to ERAS protocols have experienced significant reductions in nausea and vomiting (OR: 0.42, 95 % CI: 0.19–0.95, P-value = 0.040), intraoperative time (MD: 5.40, 95 % CI: 3.05–7.77, P-value<0.001), time to mobilization (MD: 3.78, 95 % CI: 5.46 to −2.10, P-value<0.001), intensive care unit length of stay (MD: 0.70, 95 % CI: 0.13–1.27, P-value = 0.020), total hospital stay (MD: 0.42, 95 % CI: 0.69 to −0.16, P-value = 0.002), and functional hospital stay (MD: 0.60, 95 % CI: 0.98 to −0.22, P-value = 0.002). Component-based analysis demonstrated that early mobilization, anti-emetic protocols, optimized anesthesia, and multimodal analgesia contributed most significantly to improved outcomes. We observed a clear dose-response relationship, with greater benefits in studies implementing more ERAS components.

Conclusion

ERAS protocols significantly improve recovery metrics following bariatric surgery, with certain components demonstrating greater impact than others. Early mobilization and anti-emetic protocols appear particularly beneficial, while the “Complete Recovery Bundle” demonstrates synergistic effects. We recommend a tiered implementation approach, prioritizing high-impact components, especially in resource-limited settings.

手术后增强恢复（ERAS）方案是基于证据的护理改进过程，旨在最大限度地减少手术的负面生理后果。虽然以前的研究调查了ERAS在减肥手术中的应用，但没有研究评估哪些特定成分对改善结果的贡献最大。方法：我们按照PRISMA 2020指南进行了系统回顾和荟萃分析。包括6项随机对照试验（rct），共740例患者，比较ERAS方案与减肥手术的标准治疗。我们对14个单独的ERAS元素进行了特定成分的meta回归分析，对三个实施水平（低：≤4个成分，中：5-8个成分，高：≥9个成分）进行了剂量-反应分析，并对成分进行聚类以确定协同组合。meta回归用于确定各个成分对恢复和安全结果的相对影响。结果纳入6项随机对照试验，共740例患者。患者随机分配到时代协议经历显著减少恶心、呕吐(OR: 0.42, 95% CI: 0.19—-0.95,p = 0.040),术中时间(MD: 5.40, 95%置信区间CI: 3.05 - -7.77, P-value< 0.001),时间动员(MD: 3.78, 95% CI: 5.46−2.10,P-value< 0.001),重症监护室住院时间(MD: 0.70, 95%置信区间CI: 0.13 - -1.27, p = 0.020),总住院(MD: 0.42, 95% CI: 0.69−0.16,p = 0.002),住院和功能(MD:0.60, 95% CI: 0.98 ~ - 0.22， p值= 0.002)。基于成分的分析表明，早期动员、止吐方案、优化麻醉和多模式镇痛对改善结果贡献最大。我们观察到明显的剂量-反应关系，在使用更多ERAS成分的研究中获益更大。结论eras方案显著提高了减肥手术后的恢复指标，其中某些部分的影响比其他部分更大。早期动员和止吐方案似乎特别有益，而“完全恢复包”显示协同效应。我们建议采用分层实施方法，优先考虑影响较大的组成部分，特别是在资源有限的情况下。

{"title":"Component-based approach of enhanced recovery after surgery protocols in bariatric surgery: A systematic review and meta-analysis of randomized controlled trials","authors":"Ibrahim Ezuddin M. Almaski , Yazan Jumah Alalwani , Reem Salem Alshammari , Rayyan Mohammed A. Alassiri , Salman Ahmed S. Jathmi , Aishah Mohammed Alhadi , Amal Saleh Alzahrani , Mohammed Abdulwahed Alzahrani , Ahmed Y. Azzam , Tareq A. Maani","doi":"10.1016/j.metop.2025.100376","DOIUrl":"10.1016/j.metop.2025.100376","url":null,"abstract":"<div><h3>Introduction</h3><div>Enhanced recovery after surgery (ERAS) protocols are evidence-based care improvement processes designed to minimize and reduce the negative physiological consequences of surgery. While previous studies have investigated ERAS in bariatric surgery, none have evaluated which specific components contribute most significantly to improved outcomes.</div></div><div><h3>Methods</h3><div>We performed a systematic review and meta-analysis following PRISMA 2020 guidelines. Six randomized controlled trials (RCTs) with total of 740 patients comparing ERAS protocols to standard care in bariatric surgery were included. We conducted component-specific meta-regression analysis of 14 individual ERAS elements, dose-response analysis across three implementation levels (low: ≤4 components, medium: 5–8 components, high: ≥9 components), and component clustering to identify synergistic combinations. Meta-regression was used to determine the relative impact of individual components on recovery and safety outcomes.</div></div><div><h3>Results</h3><div>Six RCTs including a total of 740 patients were included. Patients randomized to ERAS protocols have experienced significant reductions in nausea and vomiting (OR: 0.42, 95 % CI: 0.19–0.95, P-value = 0.040), intraoperative time (MD: 5.40, 95 % CI: 3.05–7.77, P-value<0.001), time to mobilization (MD: 3.78, 95 % CI: 5.46 to −2.10, P-value<0.001), intensive care unit length of stay (MD: 0.70, 95 % CI: 0.13–1.27, P-value = 0.020), total hospital stay (MD: 0.42, 95 % CI: 0.69 to −0.16, P-value = 0.002), and functional hospital stay (MD: 0.60, 95 % CI: 0.98 to −0.22, P-value = 0.002). Component-based analysis demonstrated that early mobilization, anti-emetic protocols, optimized anesthesia, and multimodal analgesia contributed most significantly to improved outcomes. We observed a clear dose-response relationship, with greater benefits in studies implementing more ERAS components.</div></div><div><h3>Conclusion</h3><div>ERAS protocols significantly improve recovery metrics following bariatric surgery, with certain components demonstrating greater impact than others. Early mobilization and anti-emetic protocols appear particularly beneficial, while the “Complete Recovery Bundle” demonstrates synergistic effects. We recommend a tiered implementation approach, prioritizing high-impact components, especially in resource-limited settings.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100376"},"PeriodicalIF":0.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144329716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of hepatic steatosis with increased plasma xanthine oxidoreductase activity: MedCity21 health examination registry 肝脂肪变性与血浆黄嘌呤氧化还原酶活性升高的关系：MedCity21健康检查登记

Metabolism open

Pub Date : 2025-06-13 DOI: 10.1016/j.metop.2025.100374

Masafumi Kurajoh , Shinya Fukumoto , Seigo Akari , Takashi Nakamura , Yuya Miki , Yuki Nagata , Tomoaki Morioka , Katsuhito Mori , Yasuo Imanishi , Toshio Watanabe , Masanori Emoto

Background

Steatotic liver disease, characterized by hepatic steatosis, increases the risk of metabolic and cardiovascular diseases. We previously reported that the plasma activity of xanthine oxidoreductase (XOR), primarily expressed in the human liver, is also associated with these diseases. The present study examined whether hepatic steatosis is associated with increased XOR activity.

Methods

This cross-sectional study included 334 participants who underwent health examinations and were not receiving urate-lowering or insulin therapy. Values for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained with vibration-controlled transient elastography were used to assess hepatic steatosis and fibrosis. Plasma XOR activity was determined with our highly sensitive assay.

Results

Median CAP, LSM, and plasma XOR activity values were 234.0 dB/m, 3.6 kPa, and 27.2 pmol/h/mL, respectively. CAP was correlated with plasma XOR activity (ρ = 0.540, P < 0.001) and subjects with hepatic steatosis (CAP ≥248 dB/m; n = 136) showed higher activity levels than those without (40.8 vs. 21.2 pmol/h/mL, P < 0.001). Multivariable regression analyses, adjusted for confounding factors including aspartate aminotransferase, alanine aminotransferase, adiponectin, and homeostasis model assessment of insulin resistance (IR), indicated associations of CAP and hepatic steatosis with plasma XOR activity (β = 0.163, P < 0.001; β = 0.086, P = 0.037, respectively). These associations remained consistent across subgroups stratified by alcohol consumption. Neither LSM nor hepatic fibrosis (LSM ≥7.9 kPa; n = 4) was associated with plasma XOR activity.

Conclusions

These results suggest that hepatic steatosis increases plasma XOR activity independent of liver enzymes, adiponectin, and IR.

背景：以肝脏脂肪变性为特征的脂肪变性肝病增加了代谢和心血管疾病的风险。我们之前报道了黄嘌呤氧化还原酶（XOR）的血浆活性，主要表达于人类肝脏，也与这些疾病有关。本研究探讨了肝脂肪变性是否与XOR活性增加有关。方法本横断面研究包括334名接受健康检查且未接受降尿酸或胰岛素治疗的参与者。控制衰减参数（CAP）和肝脏刚度测量值（LSM）通过振动控制瞬时弹性成像获得，用于评估肝脏脂肪变性和纤维化。血浆XOR活性用我们的高灵敏度测定法测定。结果CAP、LSM和血浆XOR活性中值分别为234.0 dB/m、3.6 kPa和27.2 pmol/h/mL。CAP与血浆XOR活性相关(ρ = 0.540, P <；0.001)和肝脂肪变性患者(CAP≥248 dB/m；n = 136)的活性水平高于对照组(40.8 vs. 21.2 pmol/h/mL, P <；0.001)。多变量回归分析，调整了混杂因素，包括天冬氨酸转氨酶、丙氨酸转氨酶、脂联素和胰岛素抵抗（IR）的稳态模型评估，表明CAP和肝脂肪变性与血浆XOR活性相关(β = 0.163, P <；0.001;β = 0.086, P = 0.037)。这些关联在按酒精消费分层的亚组中保持一致。无LSM和肝纤维化(LSM≥7.9 kPa；n = 4)与血浆XOR活性相关。结论肝脂肪变性增加血浆XOR活性，不依赖于肝酶、脂联素和IR。

{"title":"Association of hepatic steatosis with increased plasma xanthine oxidoreductase activity: MedCity21 health examination registry","authors":"Masafumi Kurajoh , Shinya Fukumoto , Seigo Akari , Takashi Nakamura , Yuya Miki , Yuki Nagata , Tomoaki Morioka , Katsuhito Mori , Yasuo Imanishi , Toshio Watanabe , Masanori Emoto","doi":"10.1016/j.metop.2025.100374","DOIUrl":"10.1016/j.metop.2025.100374","url":null,"abstract":"<div><h3>Background</h3><div>Steatotic liver disease, characterized by hepatic steatosis, increases the risk of metabolic and cardiovascular diseases. We previously reported that the plasma activity of xanthine oxidoreductase (XOR), primarily expressed in the human liver, is also associated with these diseases. The present study examined whether hepatic steatosis is associated with increased XOR activity.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 334 participants who underwent health examinations and were not receiving urate-lowering or insulin therapy. Values for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained with vibration-controlled transient elastography were used to assess hepatic steatosis and fibrosis. Plasma XOR activity was determined with our highly sensitive assay.</div></div><div><h3>Results</h3><div>Median CAP, LSM, and plasma XOR activity values were 234.0 dB/m, 3.6 kPa, and 27.2 pmol/h/mL, respectively. CAP was correlated with plasma XOR activity (ρ = 0.540, <em>P</em> < 0.001) and subjects with hepatic steatosis (CAP ≥248 dB/m; n = 136) showed higher activity levels than those without (40.8 vs. 21.2 pmol/h/mL, <em>P</em> < 0.001). Multivariable regression analyses, adjusted for confounding factors including aspartate aminotransferase, alanine aminotransferase, adiponectin, and homeostasis model assessment of insulin resistance (IR), indicated associations of CAP and hepatic steatosis with plasma XOR activity (β = 0.163, <em>P</em> < 0.001; β = 0.086, <em>P</em> = 0.037, respectively). These associations remained consistent across subgroups stratified by alcohol consumption. Neither LSM nor hepatic fibrosis (LSM ≥7.9 kPa; n = 4) was associated with plasma XOR activity.</div></div><div><h3>Conclusions</h3><div>These results suggest that hepatic steatosis increases plasma XOR activity independent of liver enzymes, adiponectin, and IR.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100374"},"PeriodicalIF":0.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144279192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions 肥胖：流行、原因、后果、管理、预防策略及未来研究方向

Metabolism open

Pub Date : 2025-06-12 DOI: 10.1016/j.metop.2025.100375

Sirwan Khalid Ahmed, Ribwar Arsalan Mohammed

Obesity has emerged as one of the most pressing global public health challenges of the 21st century. Obesity has reached epidemic proportions worldwide, with over 1 billion people classified as obese in 2022, representing 13 % of the global population. Since 1975, obesity rates have tripled, and projections indicate that by 2035, around 1.9 billion adults—approximately 25 % of the world's population—will be affected. Looking further ahead to 2050, it is estimated that 3.80 billion adults, representing more than half of the anticipated global adult population, will be living with overweight or obesity. The increasing burden of obesity is associated with an alarming rise in non-communicable diseases, including type 2 diabetes, cardiovascular diseases, and multiple cancers, collectively contributing to over 5 million deaths annually. Obesity is driven by complex interactions between genetic, behavioral, environmental, and socioeconomic factors, with rapid urbanization and globalization accelerating the consumption of high-calorie diets and sedentary lifestyles. While historically prevalent in high-income nations, obesity rates are now rising most rapidly in low- and middle-income countries (LMICs), with over 70 % of obese individuals living in developing nations. The economic costs of obesity are staggering, with projections estimating a global financial burden of $4.32 trillion per year by 2035, equivalent to 3 % of the global GDP. This article explores the epidemiology, determinants, health implications, and policy responses to obesity, emphasizing the urgent need for multisectoral strategies to mitigate its impact. Public health initiatives, taxation on sugar-sweetened beverages, improved food regulations, and increased physical activity promotion are essential components of evidence-based interventions. Addressing the obesity crisis requires global cooperation to implement sustainable, long-term strategies targeting both prevention and treatment.

肥胖已成为21世纪最紧迫的全球公共卫生挑战之一。肥胖症在世界范围内已成为流行病，2022年有超过10亿人被列为肥胖，占全球人口的13%。自1975年以来，肥胖率增加了两倍，预测表明，到2035年，约有19亿成年人（约占世界人口的25%）将受到影响。展望2050年，估计将有38亿成年人超重或肥胖，占预计全球成年人口的一半以上。肥胖负担的日益加重与非传染性疾病（包括2型糖尿病、心血管疾病和多种癌症）的惊人增长有关，这些疾病每年共造成500多万人死亡。肥胖是由遗传、行为、环境和社会经济因素之间复杂的相互作用驱动的，快速的城市化和全球化加速了高热量饮食和久坐不动的生活方式的消费。虽然肥胖率历来在高收入国家普遍存在，但目前在低收入和中等收入国家（LMICs）上升最快，70%以上的肥胖者生活在发展中国家。肥胖的经济成本是惊人的，据预测，到2035年，全球每年的经济负担将达到4.32万亿美元，相当于全球GDP的3%。本文探讨了肥胖的流行病学、决定因素、健康影响和政策反应，强调迫切需要多部门战略来减轻其影响。公共卫生举措、对含糖饮料征税、改进食品法规和加强促进身体活动是循证干预措施的重要组成部分。应对肥胖危机需要全球合作，实施以预防和治疗为目标的可持续长期战略。

{"title":"Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions","authors":"Sirwan Khalid Ahmed, Ribwar Arsalan Mohammed","doi":"10.1016/j.metop.2025.100375","DOIUrl":"10.1016/j.metop.2025.100375","url":null,"abstract":"<div><div>Obesity has emerged as one of the most pressing global public health challenges of the 21st century. Obesity has reached epidemic proportions worldwide, with over 1 billion people classified as obese in 2022, representing 13 % of the global population. Since 1975, obesity rates have tripled, and projections indicate that by 2035, around 1.9 billion adults—approximately 25 % of the world's population—will be affected. Looking further ahead to 2050, it is estimated that 3.80 billion adults, representing more than half of the anticipated global adult population, will be living with overweight or obesity. The increasing burden of obesity is associated with an alarming rise in non-communicable diseases, including type 2 diabetes, cardiovascular diseases, and multiple cancers, collectively contributing to over 5 million deaths annually. Obesity is driven by complex interactions between genetic, behavioral, environmental, and socioeconomic factors, with rapid urbanization and globalization accelerating the consumption of high-calorie diets and sedentary lifestyles. While historically prevalent in high-income nations, obesity rates are now rising most rapidly in low- and middle-income countries (LMICs), with over 70 % of obese individuals living in developing nations. The economic costs of obesity are staggering, with projections estimating a global financial burden of $4.32 trillion per year by 2035, equivalent to 3 % of the global GDP. This article explores the epidemiology, determinants, health implications, and policy responses to obesity, emphasizing the urgent need for multisectoral strategies to mitigate its impact. Public health initiatives, taxation on sugar-sweetened beverages, improved food regulations, and increased physical activity promotion are essential components of evidence-based interventions. Addressing the obesity crisis requires global cooperation to implement sustainable, long-term strategies targeting both prevention and treatment.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100375"},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144279193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PCSK9-promoted LDLR degradation: Recruitment or prevention of essential cofactors? pcsk9促进LDLR降解：必需辅因子的补充还是预防？

Metabolism open

Pub Date : 2025-06-01 DOI: 10.1016/j.metop.2025.100362

Rong Li , Cindy Xinyi Zhang , Junli Liu , Da-wei Zhang

引用次数: 0

Assessment of DNA glycation in the prediabetic State: Early indicator of glycemic stress 糖尿病前期DNA糖基化的评估：血糖应激的早期指标

Metabolism open

Pub Date : 2025-06-01 DOI: 10.1016/j.metop.2025.100372

Tanish Baweja , Abhishek Dikshit , Shazia Bano , Sanjiv Kumar Bansal , Sana Alam

Introduction

Glycation of nucleic acids secondary to hyperglycemia can lead to structural alterations and the formation of neoantigens. These molecular changes may elicit an early immune response. This study investigates the interaction between serum autoantibodies from prediabetic individuals and fructose-glycated human placental DNA, aiming to assess DNA glycation as a potential early indicator of glycemic stress.

Design

and Methods: To investigate structural modifications in DNA produced by glycation, purified placental DNA was incubated with fructose (25 mM) at 37 °C for 5, 10, and 15 days, followed by spectrophotometric analysis. Peripheral blood samples were collected from 50 normoglycemic (mean age: 39.70 ± 6.63 years; 26 males, 24 females) and 50 prediabetic (mean age: 40.84 ± 5.44 years; 23 males, 27 females) adult patients, matched for age, sex, body mass index, and socio-economic conditions. The presence of circulating antibodies against glycated DNA was evaluated using direct and competitive ELISA.

Results

Fructose-mediated glycation of DNA resulted in hyperchromicity and a new absorbance peak at 360 nm, indicating structural modification. Direct ELISA revealed significantly higher levels of anti-DNA autoantibodies in prediabetic sera (0.367 ± 0.225) compared to controls (0.239 ± 0.118; p = 0.003). Competitive ELISA showed that these antibodies had greater specificity for glycated DNA, with maximum inhibition by fructose-modified DNA at 37.86 ± 2.57 %, versus 23.01 ± 2.33 % for native DNA (p < 0.01).

Conclusion

The study concludes that DNA glycation occurs in prediabetic patients with intermediate hyperglycemia as a result of high blood glucose. This suggests that glycated DNA may serve as an early molecular indicator of glycemic stress, with potential applications in risk assessment and early detection strategies for individuals at risk of progressing to type 2 diabetes.

继发于高血糖的核酸基化可导致结构改变和新抗原的形成。这些分子变化可能引起早期免疫反应。本研究调查了糖尿病前期个体血清自身抗体与果糖糖化人胎盘DNA之间的相互作用，旨在评估DNA糖化作为血糖应激的潜在早期指标。设计和方法：为了研究糖基化产生的DNA的结构修饰，纯化的胎盘DNA与果糖（25 mM）在37°C下孵育5、10和15天，然后进行分光光度分析。50例血糖正常者(平均年龄39.70±6.63岁；男性26例，女性24例)，糖尿病前期50例(平均年龄40.84±5.44岁；23名男性，27名女性)成年患者，年龄、性别、体重指数和社会经济条件相匹配。使用直接和竞争性ELISA法评估针对糖基化DNA的循环抗体的存在。结果果糖介导的DNA糖基化引起高色度，并在360 nm处出现新的吸光度峰，表明结构修饰。直接ELISA检测结果显示，糖尿病前期患者血清中抗dna自身抗体水平（0.367±0.225）明显高于对照组（0.239±0.118）；p = 0.003)。竞争性ELISA法显示，这些抗体对糖基化DNA具有更高的特异性，对果糖修饰DNA的最大抑制率为37.86±2.57%，对天然DNA的最大抑制率为23.01±2.33% (p <；0.01)。结论DNA糖基化发生在糖尿病前期伴有中度高血糖的患者中，是由高血糖引起的。这表明糖基化DNA可能作为血糖应激的早期分子指标，在风险评估和2型糖尿病风险个体的早期检测策略中具有潜在的应用价值。

{"title":"Assessment of DNA glycation in the prediabetic State: Early indicator of glycemic stress","authors":"Tanish Baweja , Abhishek Dikshit , Shazia Bano , Sanjiv Kumar Bansal , Sana Alam","doi":"10.1016/j.metop.2025.100372","DOIUrl":"10.1016/j.metop.2025.100372","url":null,"abstract":"<div><h3>Introduction</h3><div>Glycation of nucleic acids secondary to hyperglycemia can lead to structural alterations and the formation of neoantigens. These molecular changes may elicit an early immune response. This study investigates the interaction between serum autoantibodies from prediabetic individuals and fructose-glycated human placental DNA, aiming to assess DNA glycation as a potential early indicator of glycemic stress.</div></div><div><h3>Design</h3><div>and Methods: To investigate structural modifications in DNA produced by glycation, purified placental DNA was incubated with fructose (25 mM) at 37 °C for 5, 10, and 15 days, followed by spectrophotometric analysis. Peripheral blood samples were collected from 50 normoglycemic (mean age: 39.70 ± 6.63 years; 26 males, 24 females) and 50 prediabetic (mean age: 40.84 ± 5.44 years; 23 males, 27 females) adult patients, matched for age, sex, body mass index, and socio-economic conditions. The presence of circulating antibodies against glycated DNA was evaluated using direct and competitive ELISA.</div></div><div><h3>Results</h3><div>Fructose-mediated glycation of DNA resulted in hyperchromicity and a new absorbance peak at 360 nm, indicating structural modification. Direct ELISA revealed significantly higher levels of anti-DNA autoantibodies in prediabetic sera (0.367 ± 0.225) compared to controls (0.239 ± 0.118; p = 0.003). Competitive ELISA showed that these antibodies had greater specificity for glycated DNA, with maximum inhibition by fructose-modified DNA at 37.86 ± 2.57 %, versus 23.01 ± 2.33 % for native DNA (p < 0.01).</div></div><div><h3>Conclusion</h3><div>The study concludes that DNA glycation occurs in prediabetic patients with intermediate hyperglycemia as a result of high blood glucose. This suggests that glycated DNA may serve as an early molecular indicator of glycemic stress, with potential applications in risk assessment and early detection strategies for individuals at risk of progressing to type 2 diabetes.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100372"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Higher serum uric acid levels and risk of all-cause mortality in general population: a systematic review and meta-analysis 高血清尿酸水平与普通人群全因死亡风险：一项系统回顾和荟萃分析

Metabolism open

Pub Date : 2025-05-16 DOI: 10.1016/j.metop.2025.100371

Md Golam Rabbani , Sheikh M. Alif , Cammie Tran , Amanda J. Rickard , Lisa Demos , John J. McNeil , Md Nazmul Karim

Background

Population-based studies have reported a relationship between high serum uric acid (SUA) levels and all-cause mortality; however, findings are inconsistent. To address this issue, we conducted a meta-analysis of general population-based studies.

Methods

A systematic search was conducted in PubMed, Ovid Medline, EMBASE, and Web of science to identify relevant peer-reviewed articles using pre-specified search terms. Population-based cohort studies investigating the association between SUA levels and all-cause mortality were included. Risk ratios (RR) for all-cause mortality were calculated for higher and lower SUA levels based on data reporting on exposure and outcome. A meta-analysis based on a log-transformed random effect maximum likelihood model was used to obtain summary risk estimates. Heterogeneity was assessed through subgroup analysis and meta-regression of the study-level covariates.

Results

Thirty-four studies with more than 2.5 million participants were identified and analysed. Higher SUA levels were associated with an increased risk of all-cause mortality (RR: 1.32; 95 % confidence intervals (CIs):1.26–1.39, p < 0.001). The risk of mortality was higher in women (RR:1.91; 95 %CI:1.40–2.61, p < 0.001) compared to men (RR:1.16; 95 %CI:1.08 1.24, p < 0.001). Subgroup analyses suggested that middle-aged adults (RR: 1.52, 95 %CI: 1.35–1.68), individuals living in OECD countries (RR:1.39, 95 %CI:1.28–1.49) and those of Caucasian ethnicity (RR:1.43, 95 %CI:1.35–1.51) reported a greater impact of elevated SUA levels on all-cause mortality.

Conclusions

Higher SUA levels were associated with a significant increase in the risk of all-cause mortality, with women appearing to be at greater risk than men. These findings highlight the need for research into mechanisms underlying the association between SUA and mortality and the reason for the sex difference identified.

背景：基于人群的研究已经报道了高血清尿酸（SUA）水平与全因死亡率之间的关系；然而，研究结果并不一致。为了解决这个问题，我们对一般人群为基础的研究进行了荟萃分析。方法系统检索PubMed、Ovid Medline、EMBASE和Web of science，使用预设检索词检索相关同行评议文章。以人群为基础的队列研究调查了SUA水平与全因死亡率之间的关系。根据报告暴露和结果的数据，计算高和低SUA水平的全因死亡率风险比（RR）。基于对数变换随机效应最大似然模型的荟萃分析被用于获得汇总风险估计。通过亚组分析和研究水平协变量的元回归来评估异质性。结果确认并分析了34项研究，参与者超过250万人。高SUA水平与全因死亡风险增加相关(RR: 1.32；95%置信区间（ci）： 1.26-1.39, p <；0.001)。女性的死亡风险更高(RR:1.91；95% CI: 1.40-2.61, p <；0.001)，与男性相比(RR:1.16；95% CI:1.08 1.24, p <；0.001)。亚组分析表明，中年人（RR: 1.52, 95% CI: 1.35-1.68）、生活在经合组织国家的个体（RR:1.39, 95% CI: 1.28-1.49）和高加索人种（RR:1.43, 95% CI: 1.35-1.51）报告了SUA水平升高对全因死亡率的更大影响。结论较高的SUA水平与全因死亡风险的显著增加相关，女性的风险似乎高于男性。这些发现强调有必要研究SUA与死亡率之间关联的潜在机制，以及确定性别差异的原因。

{"title":"Higher serum uric acid levels and risk of all-cause mortality in general population: a systematic review and meta-analysis","authors":"Md Golam Rabbani , Sheikh M. Alif , Cammie Tran , Amanda J. Rickard , Lisa Demos , John J. McNeil , Md Nazmul Karim","doi":"10.1016/j.metop.2025.100371","DOIUrl":"10.1016/j.metop.2025.100371","url":null,"abstract":"<div><h3>Background</h3><div>Population-based studies have reported a relationship between high serum uric acid (SUA) levels and all-cause mortality; however, findings are inconsistent. To address this issue, we conducted a meta-analysis of general population-based studies.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, Ovid Medline, EMBASE, and Web of science to identify relevant peer-reviewed articles using pre-specified search terms. Population-based cohort studies investigating the association between SUA levels and all-cause mortality were included. Risk ratios (RR) for all-cause mortality were calculated for higher and lower SUA levels based on data reporting on exposure and outcome. A meta-analysis based on a log-transformed random effect maximum likelihood model was used to obtain summary risk estimates. Heterogeneity was assessed through subgroup analysis and meta-regression of the study-level covariates.</div></div><div><h3>Results</h3><div>Thirty-four studies with more than 2.5 million participants were identified and analysed. Higher SUA levels were associated with an increased risk of all-cause mortality (RR: 1.32; 95 % confidence intervals (CIs):1.26–1.39, p < 0.001). The risk of mortality was higher in women (RR:1.91; 95 %CI:1.40–2.61, p < 0.001) compared to men (RR:1.16; 95 %CI:1.08 1.24, p < 0.001). Subgroup analyses suggested that middle-aged adults (RR: 1.52, 95 %CI: 1.35–1.68), individuals living in OECD countries (RR:1.39, 95 %CI:1.28–1.49) and those of Caucasian ethnicity (RR:1.43, 95 %CI:1.35–1.51) reported a greater impact of elevated SUA levels on all-cause mortality.</div></div><div><h3>Conclusions</h3><div>Higher SUA levels were associated with a significant increase in the risk of all-cause mortality, with women appearing to be at greater risk than men. These findings highlight the need for research into mechanisms underlying the association between SUA and mortality and the reason for the sex difference identified.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100371"},"PeriodicalIF":0.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recovery time of diabetic ketoacidosis in Africa: Systematic review and meta-analysis 非洲糖尿病酮症酸中毒的恢复时间：系统回顾和荟萃分析

Metabolism open

Pub Date : 2025-05-15 DOI: 10.1016/j.metop.2025.100370

Tadios Lidetu , Simon Birhanu , Addisu Simachew Asgai , Tsegaamlak Kumelachew Derse , Yideg Abinew , Moges Tadesse , Desalegn Mitiku , Jemberu Chane , Banchamilak Adane , Tadele Kassahun Wudu , Betelhem Mekonnen , Desiyalew Habtamu Tamiru

Background

Diabetes mellitus is a long-term metabolic disease marked by consistently elevated blood glucose levels. Diabetic ketoacidosis is the medical consequence of diabetes mellitus that has the highest attributed fatality rate. Socioeconomically differences affect how long it takes to recover from diabetic ketoacidosis. A few research were carried out in Africa to demonstrate how long diabetic ketoacidosis takes to recover. However, the pooled median recovery time and predictors of diabetic ketoacidosis have not been studied in Africa. Thus, determine the pooled median recovery time and predictors of diabetic ketoacidosis in Africa was the aim of this systematic review and meta-analysis.

Methods

To find available publications, a number of databases were analyzed, including PubMed, Science Direct, Cochrane, Hinari, Google Scholar, grey literature, and articles from various university repository sites. Microsoft Excel version 13 was used to extract and sort the data before exporting it to STATA/MP 17.0 for analysis. The quality of each study was evaluated using the Newcastle-Ottawa Scale. A 95 percent confidence interval Der Simonian random-effects model was employed to investigate the pooled recovery time of diabetic ketoacidosis. Publication bias and heterogeneity were assessed using the Egger's test and I². Both meta-regression and subgroup analysis were used to determine the potential source of heterogeneity. Statistical significance was defined as P-values below 0.05.

Result

The pooled median recovery time for diabetic ketoacidosis in Africa was 38 h (95 percent CI: 33–43 h), according to this comprehensive review and meta-analysis. Significant heterogeneity is evident when looking at the Galbraith plot with I2 = 100 % (p < 0.001). Research conducted after 2020 revealed that diabetic ketoacidosis has a long recovery time of 40 h (95 percent CI: 3–77 h). However, research with fewer than 300 participants showed that diabetic ketoacidosis recovered more quickly: 18 h (95 percent confidence interval: 12–24 h).

Conclusion

Among patients with diabetic ketoacidosis in Africa, the pooled median recovery time was lengthy. The recovery time from diabetic ketoacidosis was influenced by a number of factors, including the severity of the diabetic ketoacidosis, the delay in starting therapy, and the length of time the patient had diabetes mellitus, and elevated blood glucose levels. Diabetic ketoacidosis recovery time can be shortened by altering these factors.

背景：糖尿病是一种长期的代谢性疾病，其特征是血糖水平持续升高。糖尿病酮症酸中毒是糖尿病的医学后果，死亡率最高。社会经济差异影响糖尿病酮症酸中毒恢复所需的时间。在非洲进行了一些研究，以证明糖尿病酮症酸中毒需要多长时间才能恢复。然而，糖尿病酮症酸中毒的中位恢复时间和预测因素尚未在非洲进行研究。因此，确定非洲糖尿病酮症酸中毒的中位恢复时间和预测因素是本系统综述和荟萃分析的目的。方法通过PubMed、Science Direct、Cochrane、Hinari、谷歌Scholar、灰色文献和各大学知识库网站的文章等数据库进行分析。在导出到STATA/MP 17.0进行分析之前，使用Microsoft Excel version 13对数据进行提取和排序。每个研究的质量用纽卡斯尔-渥太华量表进行评估。采用95%置信区间的Der Simonian随机效应模型研究糖尿病酮症酸中毒的综合恢复时间。采用Egger’s检验和I2评估发表偏倚和异质性。采用meta回归和亚组分析来确定异质性的潜在来源。统计学显著性定义为p值小于0.05。结果根据这项综合综述和荟萃分析，非洲糖尿病酮症酸中毒的中位恢复时间为38小时（95% CI: 33-43小时）。当观察Galbraith图时，I2 = 100% (p <；0.001)。2020年后的研究发现，糖尿病酮症酸中毒的恢复时间长达40小时（95% CI: 3-77小时）。然而，少于300名参与者的研究表明，糖尿病酮症酸中毒恢复得更快：18小时（95%置信区间：12-24小时）。结论非洲地区糖尿病酮症酸中毒患者中位恢复时间较长。糖尿病酮症酸中毒的恢复时间受到许多因素的影响，包括糖尿病酮症酸中毒的严重程度、开始治疗的延迟、患者患有糖尿病的时间长短以及血糖水平升高。改变这些因素可缩短糖尿病酮症酸中毒的恢复时间。

{"title":"Recovery time of diabetic ketoacidosis in Africa: Systematic review and meta-analysis","authors":"Tadios Lidetu , Simon Birhanu , Addisu Simachew Asgai , Tsegaamlak Kumelachew Derse , Yideg Abinew , Moges Tadesse , Desalegn Mitiku , Jemberu Chane , Banchamilak Adane , Tadele Kassahun Wudu , Betelhem Mekonnen , Desiyalew Habtamu Tamiru","doi":"10.1016/j.metop.2025.100370","DOIUrl":"10.1016/j.metop.2025.100370","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes mellitus is a long-term metabolic disease marked by consistently elevated blood glucose levels. Diabetic ketoacidosis is the medical consequence of diabetes mellitus that has the highest attributed fatality rate. Socioeconomically differences affect how long it takes to recover from diabetic ketoacidosis. A few research were carried out in Africa to demonstrate how long diabetic ketoacidosis takes to recover. However, the pooled median recovery time and predictors of diabetic ketoacidosis have not been studied in Africa. Thus, determine the pooled median recovery time and predictors of diabetic ketoacidosis in Africa was the aim of this systematic review and meta-analysis.</div></div><div><h3>Methods</h3><div>To find available publications, a number of databases were analyzed, including PubMed, Science Direct, Cochrane, Hinari, Google Scholar, grey literature, and articles from various university repository sites. Microsoft Excel version 13 was used to extract and sort the data before exporting it to STATA/MP 17.0 for analysis. The quality of each study was evaluated using the Newcastle-Ottawa Scale. A 95 percent confidence interval Der Simonian random-effects model was employed to investigate the pooled recovery time of diabetic ketoacidosis. Publication bias and heterogeneity were assessed using the Egger's test and I<sup>2</sup>. Both meta-regression and subgroup analysis were used to determine the potential source of heterogeneity. Statistical significance was defined as P-values below 0.05.</div></div><div><h3>Result</h3><div>The pooled median recovery time for diabetic ketoacidosis in Africa was 38 h (95 percent CI: 33–43 h), according to this comprehensive review and meta-analysis. Significant heterogeneity is evident when looking at the Galbraith plot with I2 = 100 % (p < 0.001). Research conducted after 2020 revealed that diabetic ketoacidosis has a long recovery time of 40 h (95 percent CI: 3–77 h). However, research with fewer than 300 participants showed that diabetic ketoacidosis recovered more quickly: 18 h (95 percent confidence interval: 12–24 h).</div></div><div><h3>Conclusion</h3><div>Among patients with diabetic ketoacidosis in Africa, the pooled median recovery time was lengthy. The recovery time from diabetic ketoacidosis was influenced by a number of factors, including the severity of the diabetic ketoacidosis, the delay in starting therapy, and the length of time the patient had diabetes mellitus, and elevated blood glucose levels. Diabetic ketoacidosis recovery time can be shortened by altering these factors.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100370"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic regulation of Th17 and Treg cell balance by the mTOR signaling mTOR信号对Th17和Treg细胞平衡的代谢调节

Metabolism open

Pub Date : 2025-05-08 DOI: 10.1016/j.metop.2025.100369

Zhengzheng Wang , Zhen Xu , Ming Zong , Lieying Fan

The balance between T helper type 17 (Th17) and regulatory T (Treg) cells is crucial for maintaining immune homeostasis. The breakdown of this equilibrium is strongly associated with autoimmune disorders, though the regulatory mechanism of the Th17/Treg plasticity is less well demonstrated. The glycolytic metabolism plays a vital role in regulating the Th17/Treg cell differentiation. The review addressed the importance of mammalian target of rapamycin (mTOR) signaling in the glycolysis pathway attributed to Th17/Treg cell balance and consequence. Notably, we discuss the consequences of its equilibrium that lead to various autoimmune diseases, which might provide a new insight into the potentially therapeutic drug target for autoimmune disorders.

辅助性T细胞17 （Th17）和调节性T细胞（Treg）之间的平衡对于维持免疫稳态至关重要。这种平衡的破坏与自身免疫性疾病密切相关，尽管Th17/Treg可塑性的调节机制尚未得到很好的证实。糖酵解代谢在调节Th17/Treg细胞分化中起着至关重要的作用。本文综述了哺乳动物雷帕霉素靶（mTOR）信号在糖酵解途径中与Th17/Treg细胞平衡及其后果相关的重要性。值得注意的是，我们讨论了其平衡导致各种自身免疫性疾病的后果，这可能为自身免疫性疾病的潜在治疗药物靶点提供新的见解。

引用次数: 0

Sleep quality and well-being in obesity-hypoventilation syndrome versus obstructive sleep apnea with obesity: A comparative study 肥胖-低通气综合征与阻塞性睡眠呼吸暂停合并肥胖患者的睡眠质量和幸福感：一项比较研究

Metabolism open

Pub Date : 2025-05-04 DOI: 10.1016/j.metop.2025.100367

Vasiliki Epameinondas Georgakopoulou , Athina Lazaridou , Athanasios Voulgaris , Kostas Archontogeorgis , Maria Dalamaga , Evangelia Nena , Paschalis Steiropoulos

Background

Only a few studies in the published literature have assessed the well-being, and the sleep quality (SQ) in patients with obesity hypoventilation syndrome (OHS). The aim of this study was to evaluate well-being and SQ in patients with OHS and to compare these outcomes with those of patients with obstructive sleep apnea (OSA) and obesity.

Methods

Consecutive subjects being referred for evaluation of sleep disordered breathing were enrolled in the study. Patients were divided into two groups: Group A: OSA patients with BMI ≥30 kg/m² and 2) Group B: OHS patients. Well-being was assessed using the World Health Organization-Five Well-Being Index (WHO-5), while sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).

Results

In total 1010 participants (OHS, n = 203) were included in the study. No difference was observed between groups in mean scores of Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), WHO-5, and PSQI questionnaires. In patients with OHS, WHO-5 score was negatively correlated with neck circumference (r = −0.703, p = 0.016) and waist circumference (r = −0.728, p = 0.011). Moreover, PSQI scores in this group were significantly correlated with BMI (r = 0.410, p = 0.038). A lower WHO-5 score was observed in OHS patients with diabetes mellitus compared to non-diabetic patients with OHS (p = 0.049).

Conclusions

Patients with OSA and OHS reported similarly poor well-being and SQ. In patients with OHS, both high neck - and waist circumference were associated with poor well-being, while higher BMI was associated with worse sleep quality. Additionally, the well-being of OHS patients with concomitant diabetes mellitus was worse compared to OHS patients without diabetes mellitus.

在已发表的文献中，只有少数研究评估了肥胖低通气综合征（OHS）患者的幸福感和睡眠质量（SQ）。本研究的目的是评估OHS患者的幸福感和SQ，并将这些结果与阻塞性睡眠呼吸暂停（OSA）和肥胖患者的结果进行比较。方法纳入连续受试者进行睡眠呼吸障碍评估。患者分为两组：A组：BMI≥30 kg/m2的OSA患者；B组：OHS患者。使用世界卫生组织五幸福指数（WHO-5）评估幸福感，使用匹兹堡睡眠质量指数（PSQI）评估睡眠质量。结果共纳入1010名参与者（OHS, n = 203）。Epworth嗜睡量表（ESS）、疲劳严重程度量表（FSS）、WHO-5、PSQI问卷平均得分组间无差异。OHS患者WHO-5评分与颈围（r = - 0.703, p = 0.016）、腰围（r = - 0.728, p = 0.011）呈负相关。此外，该组PSQI评分与BMI呈显著相关（r = 0.410, p = 0.038）。OHS合并糖尿病患者的WHO-5评分低于非糖尿病OHS患者（p = 0.049）。结论OSA和OHS患者报告的幸福感和SQ相似。在OHS患者中，高颈和高腰围与较差的幸福感有关，而高BMI与较差的睡眠质量有关。此外，OHS合并糖尿病患者的幸福感较未合并糖尿病的OHS患者差。

{"title":"Sleep quality and well-being in obesity-hypoventilation syndrome versus obstructive sleep apnea with obesity: A comparative study","authors":"Vasiliki Epameinondas Georgakopoulou , Athina Lazaridou , Athanasios Voulgaris , Kostas Archontogeorgis , Maria Dalamaga , Evangelia Nena , Paschalis Steiropoulos","doi":"10.1016/j.metop.2025.100367","DOIUrl":"10.1016/j.metop.2025.100367","url":null,"abstract":"<div><h3>Background</h3><div>Only a few studies in the published literature have assessed the well-being, and the sleep quality (SQ) in patients with obesity hypoventilation syndrome (OHS). The aim of this study was to evaluate well-being and SQ in patients with OHS and to compare these outcomes with those of patients with obstructive sleep apnea (OSA) and obesity.</div></div><div><h3>Methods</h3><div>Consecutive subjects being referred for evaluation of sleep disordered breathing were enrolled in the study. Patients were divided into two groups: Group A: OSA patients with BMI ≥30 kg/m<sup>2</sup> and 2) Group B: OHS patients. Well-being was assessed using the World Health Organization-Five Well-Being Index (WHO-5), while sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).</div></div><div><h3>Results</h3><div>In total 1010 participants (OHS, n = 203) were included in the study. No difference was observed between groups in mean scores of Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), WHO-5, and PSQI questionnaires. In patients with OHS, WHO-5 score was negatively correlated with neck circumference (r = −0.703, p = 0.016) and waist circumference (r = −0.728, p = 0.011). Moreover, PSQI scores in this group were significantly correlated with BMI (r = 0.410, p = 0.038). A lower WHO-5 score was observed in OHS patients with diabetes mellitus compared to non-diabetic patients with OHS (p = 0.049).</div></div><div><h3>Conclusions</h3><div>Patients with OSA and OHS reported similarly poor well-being and SQ. In patients with OHS, both high neck - and waist circumference were associated with poor well-being, while higher BMI was associated with worse sleep quality. Additionally, the well-being of OHS patients with concomitant diabetes mellitus was worse compared to OHS patients without diabetes mellitus.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100367"},"PeriodicalIF":0.0,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A direct effect of sulfatide against development of fibrosis 硫脂对纤维化发展的直接作用

Metabolism open

Pub Date : 2025-05-01 DOI: 10.1016/j.metop.2025.100368

Rikke Thea , Karsten Buschard

引用次数: 0